Abstract
Slovenia has a sizeable domestic industry and is home to the two largest
generics companies in Europe, Krka and Lek. This report is ideal for
executives wanting to understand the key drivers in the pharmaceutical market
and have access to a wealth of statistical data, including five-year market
projections. Included with the report are 3 free quarterly updated outlook
reports, enabling you to keep up to date with market developments for a year.
Includes 3 quarterly updated outlook reports!
Slovenia is a small but relatively wealthy country, located in central
Southern Europe. A part of Yugoslavia prior to 1991, Slovenia escaped from the
collapse of that country virtually untouched by violence and ethnic warfare.
In other respects, the country more closely resembles its Western neighbours
rather than other former Communist states; demographic indicators are more in
line with Western than Eastern Europe and income levels are comparable with
those found in Southern parts of the European Union. The Slovenian
pharmaceutical market is thus relatively advanced.
The country has a sizeable domestic industry and is home to the two largest
generics companies in Europe, Krka and Lek. Slovenian pharmaceutical
regulations are aligned with EU legislation, following EU entry in May 2004
and are enforced by the Agency for Medicinal Products and Medical Devices, of
the MoH. Patent laws have come under fire in recent years, but the
introduction of the 8+2+1 formula in April 2006 helped to prevent Slovenia
being placed on the US 301 Watch List for 2007.
New pricing regulations came into effect in January 2007, which should save
US$32 million of the US$690 million currently spent on prescription drugs at
hospitals each year. Research companies have criticised the new legislation as
the price of a patented drug is now matched to the lowest price in one of the
reference countries, rather than the average. Generic prices must not exceed
85% of the average of a similar product.
View Cart
